Two Brain Sites for Cannabinoid Reward

Abraham Zangen,1,2* Marcello Solinas,1* Satoshi Ikemoto,1 Steven R. Goldberg,1 and Roy A. Wise1

1National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland 21224, and 2Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel

The recent findings that Δ9-tetrahydrocannabinol (Δ9THC), the active agent in marijuana and hashish, (1) is self-administered intravenously, (2) potentiates the rewarding effects of electrical brain stimulation, and (3) can establish conditioned place preferences in laboratory animals, suggest that these drugs activate biologically primitive brain reward mechanisms. Here, we identify two chemical trigger zones for stimulant and rewarding actions of Δ9THC. Microinjections of Δ9THC into the posterior ventral tegmental area (VTA) or into the shell of the nucleus accumbens (NAS) increased locomotion, and rats learned to lever-press for injections of Δ9THC into each of these regions. Substitution of vehicle for drug or treatment with a cannabinoid CB1 receptor antagonist caused response cessation. Microinjections of Δ9THC into the posterior VTA and into the posterior shell of NAS established conditioned place preferences. Injections into the core of the NAS, the anterior VTA, or dorsal to the VTA were ineffective. These findings link the sites of rewarding action of these regions. Substitution of vehicle for drug or treatment with a cannabinoid CB1 receptor antagonist caused response cessation.

Key words: THC; reward; locomotion; ventral tegmental area; nucleus accumbens; self-administration

Introduction

Intracranial microinjections have been used to localize mechanisms of action of several psychoactive drugs, such as the sites in the brainstem where morphine triggers its analgesic actions or the sites around the third ventricle where angiotensin induces drinking. This approach has been used to determine that amphetamine (Hoebel et al., 1983), morphine (Olds, 1982), and phencyclidine (Carlezon and Wise, 1996), have rewarding actions in nucleus accumbens (NAS; where the majority of the fibers of the mesolimbic dopamine system terminate) and that nicotine (Laviollette and van der Kooy, 2003) and μ- and δ-opioids (Bozarth and Wise, 1981; Olds, 1982; Devine and Wise, 1994; Zangen et al., 2002) have rewarding actions in the ventral tegmental area (VTA; the origin of the mesolimbic dopamine system). These agents are thought to be habit-forming because they activate the mesolimbic dopamine system or because they act on GABAergic neurons that receive input from or send output to the dopamine system (Wise, 1998).

Δ9-Tetrahydrocannabinol (Δ9THC) is self-administered intravenously (Tanda et al., 2000; Justinova et al., 2003), can establish conditioned place preferences (Valjent and Maldonado 2000), can potentiate brain stimulation reward (Gardner et al., 1988), and activates the mesolimbic dopamine system (Ng Cheong Ton et al., 1988; French, 1997; Tanda et al., 1997). Although demonstrations of rewarding effects of Δ9THC appear to be very much dependent on the experimental conditions (Parolaro et al., 2005), the brain sites at which Δ9THC can trigger these actions are not known.

In the present study, we used microinjections into subregions of the VTA and nucleus accumbens to determine whether Δ9THC has rewarding or psychomotor stimulant actions in either region. Most drugs of abuse cause psychomotor activation and do so when microinjected at the same brain sites where they have rewarding actions (Wise and Bozarth, 1987). Thus, we initially screened for drug-induced locomotor activity. Next, we examined the rewarding effect of Δ9THC in specific portions of the VTA and nucleus accumbens using intracranial self-administration. Addictive drugs not only establish compulsive self-administration habits, they also establish conditioned preferences for the portions of the environment in which the drug has been experienced. Therefore, we also used a conditioned place-preference paradigm to confirm rewarding effects of Δ9THC microinjections into subregions of the nucleus accumbens and the VTA.

Materials and Methods

Animals. Two hundred eight male Sprague Dawley rats (Charles River Laboratories, Raleigh, NC), weighing between 270 and 330 g at the time of surgery, were used for these experiments. They were housed in pairs before surgery and individually after surgery, and maintained under a reversed 12 h light/dark cycle and tested in darkness during their dark phase. Laboratory rat chow and water were continuously available in their home cages. Animals used in this study were maintained in facilities accredited by the American Association for the Accreditation of Laboratory Animal Care and the experiments were conducted in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals.

Surgical procedures. Each rat was implanted unilaterally, under pentobarbital/chloral hydrate anesthesia (31 and 142 mg/kg, respectively, with a 26-gauge guide cannula above the posterior VTA (pVTA), anterior VTA (aVTA), or nucleus accumbens shell or core. The cannulas were
angled toward the midline at 6° (VTA) to avoid penetration of the mid-sagittal sinus or at 16° (nucleus accumbens) to avoid penetration of the lateral ventricle. Stereotaxic coordinates (flat skull) were 5.0 mm posterior (P) to bregma, 1.6 mm lateral (L) to the midline, and 7.8 mm ventral (V) to the skull surface (measured along the trajectory of the angled cannula) for anterior VTA placements; 6.1 P, 1.3 L, and 7.8 V for posterior VTA placements; 6.1 P, 1.3 L, and 6.8 V for the region dorsal to the posterior VTA; 5.8 P, 2.3 L, and 8.0 V for the substantia nigra (SNr); 1.5 anterior (A), 3.8 L, and 6.2 V for the accumbens core placement; and 1.8 A, 3.2 L, and 6.6 V for the primary (midlevel) nucleus accumbens shell placement. In the last experiment, additional groups were tested with anterior (2.2 A) or posterior (1.2 A) placements in the accumbens shell. Each rat was implanted with a guide cannula in a single brain site and separate groups of rats were prepared for the locomotor activity experiments (total, n = 67), the intracranial self-administration experiments (total, n = 91), and the conditioned place preference experiments (total, n = 50). For intracranial injections, an injection cannula that protruded 1 mm below the guide cannula was used.

Drugs. Δ9THC (200 mg/ml of ethanol) was obtained from the National Institute on Drug Abuse (Rockville, MD). The ethanol was evaporated under nitrogen and the Δ9THC then dissolved in artificial CSF (aCSF) supplemented with 35% (w/v) 2-hydroxypropyl-1-cyclodextrin (Sigma-RBI, St. Louis, MO). The aCSF consisted of the following (in mM): 125 NaCl, 2.5 KCl, 0.5 NaH2PO4, 5.0 Na2HPO4, 1.0 MgCl2, and 1.2 CaCl2, pH 7.4. The maximal concentration of Δ9THC was 7.3 mM. The concentration of Δ9THC in our vehicle was analyzed weekly using gas chromatography (Giroud et al., 2001). After 6 weeks at room temp-erature, the concentration of Δ9THC decreased by 12%. Although the rate of degradation was relatively low, we cannot rule out the possibility that some derivatives could decrease the psychoactive properties of Δ9THC. Therefore, we prepared fresh Δ9THC solutions for each set of experiments. Moreover, the order of doses in the locomotion experiments was counterbalanced and we did not notice an effect of the given order of doses on the experimental outcome.

The cannabinoid CB1 receptor (CB1R) antagonist, rimonabant (SR-141716A) was obtained from the National Institute on Drug Abuse and suspended in a solution 1:1:18 of Tween 80, ethanol, and saline and administered intraperitoneally in a volume of 2 ml/kg.

Locomotion. Locomotion was estimated from beam crossings in a 40 × 40 cm open field (AccuScan Instruments, Columbus, OH). After 5 d of recovery from surgery, the rats were habituated to the test apparatus in six daily 1 h sessions. On subsequent test days, each rat received an intracranial microinfusion of Δ9THC (0, 100, 300, 1000, or 3000 pmol in aCSF, supplemented with 2-hydroxypropyl-1-cyclodextrin) or vehicle (aCSF, 0.5 μl) delivered through polyethylene tubing over 60 s. The injection was made 30 s after injection and then the rat was placed in the test apparatus. Each rat was tested for 60 min daily but was given drug injections only every other day; this was to minimize the development of conditioned locomotion. The order of doses was counterbalanced.

Intracranial self-administration. After 5 d of recovery from surgery, each rat was placed in an operant chamber equipped with two levers and cue lights 1 cm above each lever. Lever-presses on one lever (“active” lever) activated a head-mounted injection pump (Ikemoto and Sharpe, 2001), causing an intracranial injection, and illuminated the cue light above that lever for 10 s. Additional lever presses during this 10 s period were counted but did not cause further injections. Responses on the other lever (“inactive” lever) were counted but caused no injections and illuminated no cue light. Each rat was trained for five sessions; sessions were separated by 72 h. Such intervals were chosen to avoid possible dysphoric effects that may occur 24 h after administration of Δ9THC (Lepore et al., 1995). Sessions lasted 3 h. In sessions 1 through 3, the rats of each group received an 8 s, 100 nl injection of 60 or 200 pmol of Δ9THC or vehicle for each lever press. Two doses of Δ9THC were used in the accumbens shell because the results of the locomotor activity tests indicated that this area was more sensitive than the VTA to the drug. In session 4, each rat earned only vehicle. In session 5, rats that received Δ9THC in sessions 1–3 were exposed again to the same doses of Δ9THC.

To confirm that the rewarding effects of intracranial Δ9THC were receptor-mediated and not some physicochemical reaction to the injec-

tion (Wise and Hoffman, 1992), one group of rats with cannula placements in the posterior VTA and one group with cannula placements in the shell of nucleus accumbens were trained as described but were pretreated with the cannabinoid antagonist rimonabant (SR-141716A, 1 mg/kg, i.p.) 60 min before the fourth session. This dose and timing produces maximal blockade of Δ9THC’s effects (Solinas et al., 2003). These animals were pretreated with the antagonist vehicle (0.33% Tween 80 in saline) on the third and fifth days of testing.

Conditioned place preference. The conditioned place preference (CPP) test was performed in a three-compartment apparatus (MED Associates, St. Albans, VT) consisting of a narrow middle compartment connecting two large side compartments. The two side compartments differed by floor type, by wall color, and by intensity of illumination. The walls of one side chamber were black and the walls of the other side chamber were white. The illumination of the two side chambers was adjusted to balance the side preferences; the chamber with black walls was more brightly illuminated than the chamber with white walls. The illumination was adjusted until it produced equal side preference in an independent group of rats. No preconditioning tests were conducted to increase the sensitivity of the tests (Bardo et al., 1995). In the conditioning phase, the animal experienced the effects of intracranial Δ9THC in one of the two side compartments for 60 min on each of 3 d, and experienced the effects of vehicle injections in the other side compartment for 60 min on the intervening days. While in these compartments, rats received infusions of either Δ9THC (200 pmol) or vehicle every 6 min, via the microinjection system used in the self-administration experiments. The frequency of injection was selected on the basis of the self-administration experiments in the attempt to mimic the self-administered Δ9THC doses. The exposure to conditioning compartments was counterbalanced. One day after the last conditioning session, the animal was tested for conditioned place preference; it was placed in the middle compartment with the barriers removed and the times spent in each compartment were recorded over a 15 min period.

Histology. After each experiment, the animals were killed by CO2 inhalation. Evans blue (0.5 μl) was injected through the injection cannulas and the brains were removed and soaked in 4% paraformaldehyde. Thirty-micrometer frozen coronal sections were cut and examined for the tip of the injection cannula. Exclusion criteria were based on Paxinos and Watson (1998). Anterior versus posterior VTA placements were determined according to the presence (posterior) or absence (anterior) of the interpeduncular nucleus just below the VTA in the coronal slice that included the tip of the injection cannula. Reconstruction of the placement of the cannulas and microphotographs are depicted in Figure 1.

Statistical analysis. Data are expressed as the mean ± SEM of values obtained from the indicated number of rats. Locomotor or CPP data were analyzed by repeated ANOVA coupled with application of Bonferroni’s post hoc test as indicated. Data from the intracranial drug self-administration paradigm were analyzed by ANOVA with linear and quadratic trend analysis. The comparisons of interest were between days 3–5. Such comparison was performed for both the number of intracranial infusions and the preference (ratio) between the active and inactive lever presses. A significant linear trend across days 3–5 (data fit best with a straight line) confirmed that the animals did not discriminate the day 4 challenge conditions (when they earned vehicle rather than Δ9THC or when they were pretreated with the CB1 antagonist rimonabant) from the day 3 and day 5 normal reward conditions. A significant quadratic trend (data best fit with a “U” shaped function) confirmed significant response decrement in the challenge condition on day 4 and significant recovery on the normal testing condition on day 5.

Results

Effect of intracranial Δ9THC on locomotor activity

Microinjection of Δ9THC into the pVTA induced up to 60% increases in locomotor activity (F(4,40) = 2.84; p = 0.036) (Fig. 2A) within the first 5 min after the injection and remained hyperactive for over 30 min (Fig. 2C). The effect of Δ9THC micro-injection into the pVTA was dose-dependent (Fig. 2A). The total
distance traveled was 2074 ± 276 cm after vehicle and 3286 ± 480 cm after 1 nmol of THC microinjection into the posterior VTA.

However, microinjection of Δ⁹THC into the αVTA or a region just dorsal to the posterior VTA (dpVTA) failed to significantly affect locomotion (Fig. 2A). Δ⁹THC also induced modest locomotor activation (up to 40% above baseline) when injected into the shell \(F(4,60) = 3.42; p = 0.013\), but not the core, of nucleus accumbens (Fig. 2B, D). The effect of Δ⁹THC microinjection into the nucleus accumbens shell was dose-dependent (Fig. 2B). The total distance traveled was 1811 ± 217 cm after vehicle and 2601 ± 271 cm after 0.3 nmol of THC microinjection into the accumbens shell.

Self-administration of Δ⁹THC into the VTA, nucleus accumbens, and substantia nigra

Rats learned to lever-press for Δ⁹THC injections into the posterior VTA (Fig. 3A–C). During the first 3 d of training, rats receiving Δ⁹THC in the posterior VTA responded significantly more than rats that earned vehicle injections \(F(1,12) = 5.22; p = 0.041\). Rats receiving Δ⁹THC into the anterior VTA or into a site just dorsal to the VTA did not respond significantly (Fig. 3A). The average number of responses/session during the first three training days was 20.4 ± 2.1, 13.6 ± 0.7, 10.8 ± 0.8 and 9.9 ± 1.4 for the pVTA, αVTA, dpVTA, and pVTA-vehicle groups, respectively. With posterior VTA injections, the animals learned to press the active lever regularly (Fig. 3B) and prefer it over the inactive lever (Fig. 3C) within the first training session. Responding was significantly depressed on day 4, when vehicle was substituted for drug, and recovered on day 5, when drug reward was reinstated (Fig. 3A). This was reflected in both the intake data \(F(1) = 8.20; p = 0.0125\) and the preference data \(F(1) = 21.82; p = 0.0004\) for animals receiving Δ⁹THC in the posterior VTA and in both the intake data \(F(1) = 11.27; p = 0.0057\) and the preference data \(F(1) = 14.38; p = 0.0026\) for animals receiving Δ⁹THC in the anterior VTA. In each case, the data were best fit by a quadratic trend (U function) that reflected depression on day 4 and recovery on day 5. Responding in the dorsal and vehicle control groups was linear across the 3 d; neither vehicle substitution nor reinstatement of reward altered the behavior of the dorsal control group.

Rats also learned to self-administer Δ⁹THC injections into the shell region of the nucleus accumbens (Fig. 4A). Rats receiving either dose of Δ⁹THC in the shell region responded more over the first three training days than did rats receiving vehicle \(F(2,18) = 3.58; p = 0.049\). The average number of responses/session during the first three training days was 15.9 ± 0.7, 12.9 ± 0.9, 10.1 ± 0.2, 9.5 ± 0.7 and 7.4 ± 0.9 for the shell (200 pmol/infusion), shell (66 pmol/infusion), core (200 pmol/infusion), core-vehicle, and shell-vehicle groups, respectively. With shell injections, responding was sustained and regular throughout sessions when Δ⁹THC was available (Fig. 4B). Responding extinguished on the fourth day, when vehicle was substituted for drug, and was reinstated on the fifth day, when drug was again made available (Fig. 4A). This was reflected in the intake but not the preference data for days 3–5 in animals lever-pressing for Δ⁹THC in the core of nucleus accumbens or for animals receiving vehicle in either area. Discrimination between the active and inactive levers was not significantly different between days 3–5 for animals receiving Δ⁹THC injections into the posterior VTA. In each case, the data were best fit by a quadratic trend (U function) that reflected depression on day 4 and recovery on day 5. Responding in the dorsal and vehicle control groups was linear across the 3 d; neither vehicle substitution nor reinstatement of reward altered the behavior of the dorsal control group.

When other groups of animals self-administering Δ⁹THC into the VTA, nucleus accumbens or for animals receiving vehicle in either area. Discrimination between the active and inactive levers was not significantly different between days 3–5 for animals receiving Δ⁹THC injections into the posterior VTA. In each case, the data were best fit by a quadratic trend (U function) that reflected depression on day 4 and recovery on day 5. Responding in the dorsal and vehicle control groups was linear across the 3 d; neither vehicle substitution nor reinstatement of reward altered the behavior of the dorsal control group.
into the VTA ($F_{(1)} = 7.91; p = 0.0101$) or into the shell of nucleus accumbens ($F_{(1)} = 9.51; p = 0.0064$).

None of the four rats prepared with substantia nigra cannulas learned to lever-press for $\Delta^{9}$THC injections.

Effect of intracranial $\Delta^{9}$THC injections on conditioned place preference

Rats developed significant preferences for the compartment where they experienced posterior but not anterior VTA injections of $\Delta^{9}$THC (Fig. 5). No significant preferences for the drug-associated compartment were observed in rats that had been given their injections into the middle of the accumbens shell. Because recent reports suggest differential involvement of the anterior and posterior portions of the shell of nucleus accumbens in motivation (Martin et al., 2002; Reynolds and Berridge, 2002), additional groups were tested with more anterior or more posterior placements in accumbens shell. Modest conditioned place preferences were established in the animals given their injections in the posterior but not the anterior shell of nucleus accumbens (Fig. 5). Statistical analysis revealed a significant treatment/site interaction ($F_{(4,45)} = 3.667; p = 0.001$) and the Bonferroni’s post hoc test indicated a significant effect of treatment in the posterior VTA and the posterior nucleus accumbens sites.

Discussion

The present study identifies two brain trigger zones for rewarding effects of $\Delta^{9}$THC: one in the VTA and one in the nucleus accumbens shell. The effective sites of action appear to be reasonably well localized to the posterior VTA and the posterior portion of the accumbens shell, as injections in nearby regions were either ineffective or markedly less effective in each paradigm. Drug reward was evident in both the intracranial drug self-administration paradigm and in the conditioned place-preference paradigm.

Figure 2. Distance traveled in response to $\Delta^{9}$THC or vehicle infusions into various brain regions. The effects of various doses injected into the pVTA ($n = 11$), aVTA ($n = 13$), or dpVTA ($n = 8$) (A), or into the shell ($n = 16$) or core ($n = 13$) of nucleus accumbens (B) are presented. 

C.D. Time course of the $\Delta^{9}$THC or vehicle effects on the locomotor activity. **$p < 0.01$; post hoc comparison after significant ANOVA for repeated measures main effect; Bonferroni’s post hoc test. Error bars indicate SE.

None of the four rats prepared with substantia nigra cannulas learned to lever-press for $\Delta^{9}$THC injections.

Figure 3. Intra-VTA self-administration of 200 pmol infusions of $\Delta^{9}$THC or vehicle (VEH) as a function of injection site and test session. A, Number of earned infusions. B, Temporal pattern of responding for a representative animal receiving $\Delta^{9}$THC in the pVTA on days 3–5. C. The responses on the “active” and “inactive” levers. D, E. Effect of the CB1 antagonist, rimonabant, or its vehicle on self-administration of $\Delta^{9}$THC into the posterior VTA as measured by number of earned infusions (D) and “active”/“inactive” lever responses (E). Error bars indicate SE.
The finding that $\Delta^{2}$-THC was self-administered into the posterior VTA and dependent on CB1R activation (Fig. 3D) is somewhat surprising given the low levels of CB1R (Herkenham et al., 1991) in that region. Indeed, CB1R mRNA is expressed in GABAergic striatonigral and striatopallidal neurons (Hohmann and Herkenham, 2000), only a small fraction of which project to the VTA. Indeed, CB1R mRNA is expressed preferentially in the dorsal and lateral portions of the striatum, the least likely portion of the striatum to project to VTA. This explains why there is dense CB1R binding in the zona reticulata of the SNr and only very weak CB1R binding in the VTA. Nevertheless, recent data suggest that CB1 receptors are present and modulate neurotransmission in the VTA (for review, see Lupica et al., 2004). In addition, because animals with injection cannulas directed to the SNr did not learn to lever press for $\Delta^{2}$-THC injection at this site, we conclude that diffusion to the SNr does not explain the rewarding effects of $\Delta^{2}$-THC in the posterior VTA. It is important to note that, although electrical stimulation of zona compacta of the substantia nigra (SNc) is rewarding, neither the SNr, where CB1R binding is strong, or the SNc, where CB1R binding is similar to that seen in VTA, has been reported as a site of rewarding drug injections.

Several findings suggest that the anterior and posterior VTA play differential roles in reward function. Microinjections of GABA agonists and GABA antagonists can each be rewarding (Ikemoto et al., 1997a, 1998; Laviolette and van der Kooy, 2001), depending on whether they are given in the anterior or posterior portions of the structure (Ikemoto et al., 1997a, 1998), and depending on which of the GABAergic outputs of the region are activated (Laviolette and van der Kooy, 2001). In addition, the opiate $\mu$-receptor agonist endomorphin-1 (Zangen et al., 2002), the cholinergic receptor agonist carbachol (Ikemoto and Wise, 2002), ethanol (Rodd-Henricks et al., 2000), or acetaldehyde (Rodd et al., 2004) are self-administered into the posterior VTA, but not the anterior VTA. Finally, overexpression of the AMPA receptor subunit GluR1 or of phospholipase C (a protein involved in neurotrophic signaling) in the anterior VTA potentiates systemic morphine reinforcement, whereas overexpression in the posterior VTA makes morphine aversive (Carlezon et al., 2000; Bolanos et al., 2003). The present results with THC add to the findings suggesting functional differentiation between these two portions of the VTA.
That injections into the shell of the nucleus accumbens were effective, whereas injections into the core were not, fits with the fact that systemic Δ⁹-THC releases dopamine in the shell but not the core of accumbens (Tanda et al., 1997) and is consistent with the findings that nomifensine, cocaine, a mixture of dopamine D₁ and D₂ agonists (Ikemoto et al., 1997b), and phencyclidine are self-administered into the shell much more readily than into the core (Carlezon and Wise, 1996; Ikemoto et al., 1997a; Ikemoto 2003). It is surprising, however, that conditioned place preferences were not established with injections into the same midlevel portion of the shell where the drug was self-administered. Because reward function is greatly decreased if the reward is delayed from the time of the instrumental response (Black et al., 1985), the intracranial drug self-administration paradigm is expected to be more sensitive to placement accuracy than the conditioned place-preference paradigm. In place-preference conditioning, immediacy is less important and more time is available for a drug to diffuse to its target from an off-target injection site. Nonetheless, Δ⁹-THC failed to establish conditioned place preferences when injected into the midshell site where the drug was self-administered. A modest place preference, weaker than that established with posterior VTA injections, was established with posterior accumbens shell injections. This is consistent with the impression that VTA self-administration of the drug was more robust than accumbens self-administration.

That posterior shell injections caused place preferences, whereas anterior or midlevel shell injections did not, fits well with recent findings (Martin et al., 2002) that the posterior accumbens is more involved than the anterior accumbens in the reinforcing effects of intravenous heroin. It does not fit obviously with the suggestions of Reynolds and Berridge (2002) that the anterior shell is more involved than the anterior accumbens in mediating reward. It does not seem likely on present knowledge, that smoked cannabis in humans. There are potential species differences in responsiveness to the rewarding action Δ⁹-THC, and smoked cannabis delivers the active ingredient to brain sites not reached by our intracranial injections. It is possible, although it does not seem likely on present knowledge, that smoked cannabis activates reward sites in other structures and that it does not reach concentrations in the brain sufficient to activate one or both of the sites we studied here. That caveat notwithstanding, the present data suggest that the habit-forming effects of cannabis share more with such addictive drugs as cocaine and heroin than with drugs such as hallucinogens that have their known actions in different substrates and are not self-administered by lower animals.

References